Hailie Smartinhaler Cleared for Use With Airsupra, Breztri Aerosphere

The Food and Drug Administration (FDA) has cleared the Hailie^® Smartinhaler^® for use with AstraZeneca’s Airsupra^® (albuterol and budesonide) and Breztri^® Aerosphere^® (budesonide, glycopyrrolate, and formoterol fumarate) inhalation devices.

Airsupra is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. Breztri Aerosphere is approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

The Bluetooth^®-enabled Hailie sensor attaches to the inhaler and is then paired with the Hailie^® app. The system is designed to help with treatment adherence by tracking medication use and reminding patients if a dose is missed. 

Patients are able to share adherence reports with clinicians by uploading the data to a secure cloud-based portal. This remote patient management platform allows health care providers to review the patient’s medication usage and make treatment decisions based on real-time data.

“Our mission at Adherium has always been to revolutionise the way respiratory conditions are managed,” said Dr Paul Mastoridis, CEO of Adherium. “By securing FDA clearance for our Smartinhaler with Airsupra and Breztri, we’re bringing that vision to life, offering patients and health care providers a powerful tool in the fight against chronic respiratory diseases.”

In addition to Airsupra and Breztri, the Hailie sensor is compatible with multiple asthma and COPD medications.